AzTrials
AzTrials

Irritable Bowel SyndromeNCT05631860

Psychological Risk Factors for Functional Somatic Disorders

An observational study of Irritable Bowel Syndrome and Fibromyalgia, run by University of Aarhus.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to explore the role of neuroticism, perceived stress, and adverse life events, respectively, in the development and perpetuation of functional somatic disorders. Read more about this study

Who is it for?
Ages 18 to 84 years
How many people
7,493 participants
Where
No sites listed yet
Study dates
10 Nov 2011to 30 Aug 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 84 years
  • All sexes
  • Adult, Older adult

Study population: A total of 28773 participants were randomly drawn from the adult general Danish population by means of the the Danish Civil Registration system. The DanFunD baseline cohort comprises a total of 9,656 (33.7% of invited participants) men and women aged 18-76 years, born in Denmark, and living in the Western part of greater Copenhagen. The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).

Who may be able to join

  • None

Who cannot join

  • Not born in Denmark
  • Not being a Danish citizen
  • Pregnancy

About this study

Official title: Are Neuroticism, Perceived Stress, and Adverse Life Events Risk Factors for Functional Somatic Disorders: DanFunD

The objective of this study is to explore the role of neuroticism, perceived stress, and adverse life events, respectively, in the development and perpetuation of functional somatic disorders.

Read the detailed description

Functional somatic disorders (FSD) are common disorders with a multifactorial aetiology involving biological, social, and psychological factors. An often used explanation of the illness mechanisms behind FSD which is provided to the patients is, that FSD may be understood as a multi systemic physical response to stress. This relationship can be modelled as proposed in the Cognitive Behavioural Therapy (CBT) model of emotional distress where several cognitive, behavioural and psychological factors are thought to contribute to the onset and perpetuation of FSD. Personality traits e.g. neuroticism contribute to give rise to our cognitive, behavioural, and psychological reactions. Furthermore, neuroticism with its heightened reactivity to stressors, has shown to be an important predictor of a generic vulnerability to both physical and psychological conditions. Having been exposed to previous adverse life events/traumas and childhood adversities has also showed to impact the risk of having FSD. This relationship has been proposed to be induced by a heightened response to stimuli, i.e. sensitisation, caused by physical and emotional distress triggering a hormonal cascade in the hypothalamus pituitary adrenal (HPA) axis.

So far, most studies into these aspects have been carried out in selected patient samples, and general population-based studies including a large randomly obtained sample are sparse. In three recent population-based studies, strong associations between FSD and neuroticism, perceived stress, and the accumulated number of experienced adverse life events (ALE), respectively, have been established. However, these studies were cross-sectional, thereby not providing insight to whether these factors were risk factors of FSD. More studies are needed for further elucidation on these aspects.

Objective The objective of this study is to explore the role of neuroticism, perceived stress, and the accumulated number of ALE, respectively, in the development and perpetuation of FSD.

Hypotheses

  1. Higher neuroticism, higher perceived stress, and higher number of ALE at baseline are individual risk factors of having developed FSD in the 5-year period from baseline to follow-up: FSD non-case at baseline → FSD case at follow-up
  2. Neuroticism, perceived stress, and the accumulated number of ALE positively contribute to the perpetuation of FSD from baseline to follow-up:

FSD case at baseline → FSD case at follow-up

Analytical plan All analyses will be performed using STATA version 17.0. Descriptive statistics will be presented for all the three continuous explanatory variables across FSD diagnoses. Depending on data distribution, descriptive statistics will be presented as means and standard deviations or medians and interquartile ranges.

Depending on number of incident and perpetuating cases at follow-up, a range of analyses will be conducted with the purpose of investigating if higher neuroticism, higher perceived stress, and higher accumulated number of ALE at baseline

  1. are individual risk factors for the development of FSD from baseline to follow-up
  2. are positively contributing to the perpetuation of an FSD from baseline to follow-up

The first choice of analyses For hypothesis one, multiple logistic regression models will be performed with incident FSD cases at follow-up as primary outcome and baseline neuroticism, perceived stress, and accumulated number of ALE as explanatory primary variables. The effect of neuroticism, perceived stress, and the accumulated number of ALE will be reported from the same analysis as the effect when controlled for the effect from the other primary explanatory variables. Odds ratio (OR) with 95% confidence intervals (CI) will be used as measure of association; an OR > 1 supports the hypothesis. The reference group will constitute participants without FSD at both baseline and follow-up. Reference value of neuroticism, perceived stress, and the accumulated number of ALE will be set as the median value of the total sample. In each analysis there will be controlled for the confounding effect of sex (with male as reference) and age (the median value of the total sample).

For hypothesis two, multiple logistic regression models will be performed with FSD cases perpetuating from baseline to follow-up as primary outcome and baseline neuroticism, self-perceived stress, and accumulated number of ALE as primary explanatory variable. The effect of neuroticism, perceived stress, and the accumulated number of ALE will be reported from the same analysis as the effect when controlled for the effect from the other primary explanatory variables. Odds ratio (OR) with 95% confidence intervals (CI) will be used as measure of association; an OR > 1 supports the hypothesis. The reference group will constitute participants with FSD at baseline but without FSD at follow-up. Reference value of neuroticism, perceived stress, and the accumulated number of ALE will be set as the median value of the total sample. In each analysis there will be controlled for the confounding effect of sex (with male as reference) and (the median value of the total sample).

The second choice of analyses

If number of incident and perpetuated cases at follow-up are too low to perform the above multiple logistic regression models with incorporation of the three primary explanatory variables in one analyses per FSD definition, it will be investigated if the confounding primary explanatory variables can be reduced into one variable and incorporated in separate analyses instead. Hence, instead of performing one analysis per FSD definition, three logistic regression analyses will be performed for each FSD definition:

  1. An analysis investigating the effect of baseline neuroticism (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) perceived stress and the accumulated number of ALE reduced into one variable, 2) sex, and 3) age.
  2. An analysis investigating the effect of baseline perceived stress (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) neuroticism and the accumulated number of ALE reduced into one variable, 2) sex, and 3) age.
  3. An analysis investigating the effect baseline accumulated number of ALE (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) neuroticism and perceived stress reduced into one variable, 2) sex, and 3) age.

To find out if the confounding primary explanatory variables can be reduced into one variable, principal component analyses will be performed.

The third choice of analyses If the second set of analyses cannot provide us with meaningful variables describing the primary explanatory variables, separate logistic regression analyses investigating the effect of neuroticism, perceived stress, and the accumulated number of ALE, respectively, will be performed with pre-defined prioritisation of confounders. The prioritisation will be as follows (depending on the primary explanatory variable): 1) neuroticism, 2) perceived stress, 3) accumulated number of ALE, 4) sex, and 5) age.

Medical subject headings
Irritable Bowel Syndrome, Fibromyalgia, Fatigue Syndrome, Chronic, Somatoform Disorders, Medically Unexplained Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05631860
Study groupRoleWhat they receive
DanFunD baselineThe baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).
DanFunD 5-years follow-up investigationThe follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Questionnaire-defined Functional somatic disorder at baseline

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires.

    Measured: At the DanFunD baseline investigation

  2. Interview-based Functional somatic disorder at baseline

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews.

    Measured: At the DanFunD baseline investigation

  3. Questionnaire-defined Functional somatic disorder at 5-year follow-up

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires.

    Measured: At the DanFunD 5-year follow-up investigation

  4. Interview-based Functional somatic disorder at 5-year follow-up

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews.

    Measured: At the DanFunD 5-year follow-up investigation

  5. Irritable bowel at baseline

    Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires

    Measured: At the DanFunD baseline investigation

  6. Irritable bowel at 5-year follow-up

    Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires

    Measured: At the DanFunD 5-year follow-up investigation

  7. Chronic widespread pain at baseline

    Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires

    Measured: At the DanFunD baseline investigation

  8. Chronic widespread pain at 5-year follow-up

    Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires.

    Measured: At the DanFunD 5-year follow-up investigation

  9. Chronic fatigue at baseline

    Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires.

    Measured: At the DanFunD baseline investigation

  10. Chronic fatigue at 5-year follow-up

    Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires.

    Measured: At the DanFunD 5-year follow-up investigation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2022
  2. Study start10 Nov 2011
  3. Primary completion4 Jan 2021
  4. Study completion30 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
7,493 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05631860
Sponsor's protocol ID
DanFunD psychol. risk factors
Status last verified
Nov 2022
First submitted
8 Nov 2022
Last updated
5 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Restrictions apply to the availability of data according to Danish law, which means that data cannot be made publicly available. A request for collaboration or access to data can be sent to ckff@regionh.dk. An application for data should consist of a short synopsis of the study planned. Please see our website (www. danfund.org) for more information.

Questions about this trial

What is this clinical trial studying?

An observational study of Irritable Bowel Syndrome and Fibromyalgia, run by University of Aarhus.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Questionnaire-defined Functional somatic disorder at baseline (time frame: At the DanFunD baseline investigation). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2022; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in